Human Chorionic Gonadotropin Market Report 2026

Human Chorionic Gonadotropin Market Overview

• Human Chorionic Gonadotropin market size has reached to $1.02 billion in 2025 • Expected to grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Rising Infertility Rates to Fuel Growth In Human Chorionic Gonadotropin Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Chorionic Gonadotropin Market?

Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy. It is produced by the placenta shortly after the embryo implants in the uterus. hCG plays a critical role in maintaining pregnancy by stimulating the corpus luteum (a structure in the ovary) to produce progesterone, which supports the uterine lining and prevents it from breaking down. The main technologies of human chorionic gonadotropin are natural source extraction and recombinant technology. Recombinant technology refers to a laboratory method that involves combining DNA fragments from different organisms to create new genetic combinations. The therapeutic areas are female infertility treatment, oligospermic treatment, male hypogonadism, and others, and are distributed through several channels including hospital pharmacies, retail pharmacies, and online pharmacies. The various end users involved are fertility clinics, research institutions, and others.

What Is The Human Chorionic Gonadotropin Market Growth Forecast?

The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand for assisted reproductive technologies, increasing adoption of recombinant hormones, growing focus on precision fertility treatments, expansion of online and retail pharmacy distribution, increasing investment in reproductive health research. Major trends in the forecast period include increasing use of hCG in assisted reproductive treatments, rising demand for hormonal therapies in infertility management, growing adoption of recombinant hCG products, expansion of hCG applications in male hormonal disorders, increasing focus on standardized and high-purity hormone formulations.

Global Human Chorionic Gonadotropin Market Segmentation

1) By Technology: Natural Source Extraction, Recombinant Technology 2) By Therapeutic Area: Female Infertility Treatment, Oligospermic Treatment, Male Hypogonadism, Other Therapeutic Areas 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Fertility Clinics, Research Institutions, Other End Users Subsegments: 1) By Natural Source Extraction: Extraction From Pregnant Women's Urine, Purified Urinary hCG (u-hCG) Formulations 2) By Recombinant Technology: Recombinant Hcg, Recombinant Hcg For Therapeutic Use, Recombinant Hcg For Diagnostic Applications

What Are The Drivers Of The Human Chorionic Gonadotropin Market?

An increasing rate of infertility is expected to drive the growth of the human chorionic gonadotropin market going forward. Infertility refers to the inability to conceive after at least one year of consistent, unprotected intercourse. The infertility rate is increasing with the growing prevalence of individuals and couples experiencing difficulties in conceiving due to factors such as delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin (hCG) is used in infertility treatments to stimulate ovulation in women and support testosterone production in men, facilitating the release of eggs and improving fertility outcomes. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, infertility affected around 17.5% of the adult population, or roughly one in every six people worldwide, highlighting the critical need to improve access to inexpensive, high-quality fertility care for individuals in need. Therefore, an increasing rate of infertility is driving the growth of the human chorionic gonadotropin industry. The rise in aging population is expected to drive the growth of the human chorionic gonadotropin market going forward. An aging population refers to a growing proportion of older individuals within a society due to increased life expectancy and declining birth rates. The aging population is increasing due to advancements in healthcare that have extended life expectancy. Human chorionic gonadotropin (hCG) is used by the aging population to help support hormone balance and maintain testosterone levels. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the rise in aging population is driving the growth of the human chorionic gonadotropin market.

Key Players In The Global Human Chorionic Gonadotropin Market

Major companies operating in the human chorionic gonadotropin market are Ferring Pharmaceuticals, Merck KGaA, Organon, IBSA Institut Biochimique, Teva Pharmaceutical Industries, Sandoz, Sun Pharmaceutical Industries, Cipla, Zydus Lifesciences, Lupin, Intas Pharmaceuticals, Hikma Pharmaceuticals, Aspen Pharmacare, Menarini Group, Bharat Serums and Vaccines, Serum Institute of India, LG Chem Life Sciences, Dong-A ST, Livzon Pharmaceutical Group, SciGen

What Are Latest Mergers And Acquisitions In The Human Chorionic Gonadotropin Market?

In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired the five brands from Menarini for an undisclosed sum. With this acquisition, Lupin aims to expand its portfolio and strengthen its presence in key therapeutic areas by integrating five established brands from Menarini. Menarini Group is an Italy-based pharmaceutical and diagnostics company that provides services related to human chorionic gonadotropin (hCG).

Regional Outlook

North America was the largest region in the human chorionic gonadotropin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Chorionic Gonadotropin Market?

The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Chorionic Gonadotropin Market Report 2026?

The human chorionic gonadotropin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.